MDxHealth Announces Leadership Changes with New Board Appointment and CFO Resignation

MDxHealth ( (MDXH) ) has shared an update.

On July 3, 2025, MDxHealth announced the appointment of Michael Holder as the new Chair of the Audit Committee on its Board of Directors, succeeding Regine Slagmulder. Holder brings over 30 years of diverse experience in biotech, medtech, and pharma industries, enhancing the company’s strategic and financial expertise. Additionally, the company disclosed the resignation of CFO Ron Kalfus, effective July 30, 2025, with Scott McMahan stepping in as interim CFO. These leadership changes are expected to bolster MDxHealth’s growth and operational focus in the urology market.

The most recent analyst rating on (MDXH) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on MDxHealth stock, see the MDXH Stock Forecast page.

Spark’s Take on MDXH Stock

According to Spark, TipRanks’ AI Analyst, MDXH is a Neutral.

MDxHealth’s strong revenue growth and market momentum are significant positives, driven by robust performance in prostate cancer diagnostics. However, financial instability due to high leverage, negative profitability, and valuation challenges temper the overall score.

To see Spark’s full report on MDXH stock, click here.

More about MDxHealth

MDxHealth is a leading precision diagnostics company that specializes in providing actionable molecular information to personalize patient diagnosis and treatment. The company’s tests, based on proprietary genomic, epigenetic, and other molecular technologies, assist physicians in diagnosing and prognosing urologic cancers and other urologic diseases. MDxHealth operates its U.S. headquarters and laboratory in Irvine, California, with additional laboratory operations in Plano, Texas, and its European headquarters in Herstal, Belgium.

Average Trading Volume: 67,071

Technical Sentiment Signal: Sell

Current Market Cap: $104.9M

For a thorough assessment of MDXH stock, go to TipRanks’ Stock Analysis page.